{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:44:38Z","timestamp":1700613878904},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00228-023-03576-3","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:01:55Z","timestamp":1696237315000},"page":"1657-1664","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation"],"prefix":"10.1007","volume":"79","author":[{"given":"M.","family":"Smerikarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bozhanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tournev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Maslarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"issue":"1","key":"3576_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/ejhf.1695","volume":"22","author":"ML M\u00fcller","year":"2020","unstructured":"M\u00fcller ML, Butler J, Heidecker B (2020) Emerging therapies in transthyretin amyloidosis \u2013 a new wave of hope after years of stagnancy? Eur J Heart Fail 22(1):39\u201353","journal-title":"Eur J Heart Fail"},{"key":"3576_CR2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DDDT.S289772","volume":"15","author":"A Burton","year":"2021","unstructured":"Burton A, Casta\u00f1o A, Bruno M et al (2021) Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des Devel Ther 15:1225\u20131243","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"3576_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","volume":"7","author":"R Mundayat","year":"2018","unstructured":"Mundayat R, Stewart M, Alvir J et al (2018) Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther 7(1):87\u2013101","journal-title":"Neurol Ther"},{"issue":"1","key":"3576_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL et al (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8(1):1\u201318","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3576_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1060028019888489","volume":"54","author":"J Park","year":"2020","unstructured":"Park J, Egolum U, Parker S et al (2020) Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy. Ann Pharmacother 54(5):470\u2013477","journal-title":"Ann Pharmacother"},{"issue":"2","key":"3576_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T et al (2021) Efficacy of Tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Hear Fail 9(2):115\u2013123","journal-title":"JACC Hear Fail"},{"issue":"1","key":"3576_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE et al (2016) Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 5(1):1\u201325","journal-title":"Neurol Ther"},{"issue":"7","key":"3576_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cpdd.789","volume":"9","author":"PA Lockwood","year":"2020","unstructured":"Lockwood PA, Le VH, O\u2019Gorman MT et al (2020) The bioequivalence of tafamidis 61-mg free acid capsules and Tafamidis meglumine 4 \u00d7 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev 9(7):849\u2013854","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"3576_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.126526","volume":"4","author":"C Monteiro","year":"2019","unstructured":"Monteiro C, Mesgazardeh JS, Anselmo J et al (2019) Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight 4(12):1\u201317","journal-title":"JCI Insight"},{"issue":"2","key":"3576_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40119-021-00226-6","volume":"10","author":"L Gentile","year":"2021","unstructured":"Gentile L, Tournev I, Amass L et al (2021) Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS. Cardiol Ther 10(2):481\u2013490","journal-title":"Cardiol Ther"},{"issue":"7","key":"3576_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520\u2013528","journal-title":"Eur Heart J"},{"issue":"5","key":"3576_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","volume":"263","author":"A Cortese","year":"2016","unstructured":"Cortese A, Vita G, Luigetti M et al (2016) Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263(5):916\u2013924","journal-title":"J Neurol"},{"key":"3576_CR13","doi-asserted-by":"crossref","unstructured":"Gagliardi C, Gospodinova M, Longhi S et al (2015) Glu89Gln transthyretin-related amyloidosis in Italy and Bulgaria: does geographic area influence phenotype beyond the shared mutation? Orphanet J Rare Dis 10(S1):P23. Proceedings of the First European Congress on Hereditary ATTR amyloidosis; November 2\u20133, 2015; Paris, France","DOI":"10.1186\/1750-1172-10-S1-P23"},{"key":"3576_CR14","unstructured":"Milanov I, Tournev I (2019) National consensus for diagnosis, treatment, follow-up and prevention of hereditary transthyretin amyloidosis. Bulgarian Neurology 20:1\u201330 (Bulgarian)"},{"key":"3576_CR15","doi-asserted-by":"crossref","unstructured":"Gospodinova M, Sarafov S, Guergueltcheva V et al (2015) Cardiomyopathy and peripheral polyneuropathy severity in patients with Glu89Gln mutation at the time of diagnosis. Orphanet J Rare Dis 10(S1):P59. Proceedings of the First European Congress on Hereditary ATTR amyloidosis; November 2\u20133, 2015; Paris, France","DOI":"10.1186\/1750-1172-10-S1-P59"},{"key":"3576_CR16","doi-asserted-by":"crossref","unstructured":"Gospodinova M, Sarafov S, Guergueltcheva V et al (2015) Cardiac involvement and clinical follow up of patients with hereditary transthyretin related amyloidosis associated with Glu89Gln mutation. Orphanet J Rare Dis 10 (S1):P54. Proceedings of the First European Congress on Hereditary ATTR amyloidosis; November 2\u20133, 2015; Paris, France","DOI":"10.1186\/1750-1172-10-S1-P54"},{"key":"3576_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.2459\/JCM.0000000000001036","volume":"21","author":"M Gospodinova","year":"2020","unstructured":"Gospodinova M, Sarafov S, Chamova T et al (2020) Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation. J Cardiovasc Med (Hagerstown) 21:688\u2013695","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"3576_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.15403\/jgld-362","volume":"28","author":"R Nakov","year":"2019","unstructured":"Nakov R, Sarafov S, Nakov V et al (2019) Gastrointestinal manifestations in hereditary transthyretin amyloidosis associated with Glu89Gln mutation. J Gastrointest Liver Dis 28(4):421\u2013426","journal-title":"J Gastrointest Liver Dis"},{"issue":"9","key":"3576_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/chromsci\/bmab132","volume":"60","author":"M Smerikarova","year":"2022","unstructured":"Smerikarova M, Bozhanov S, Maslarska V et al (2022) Determination of tafamidis plasma concentrations in amyloidosis patients with Glu89Gln mutation by HPLC-UV detection. J Chrom Sci 60(9):840\u2013847","journal-title":"J Chrom Sci"},{"key":"3576_CR20","unstructured":"Sarafov S (2020) Clinical-genetic and epidemiological studies in transthyretin familial amyloid polyneuropathy and in hereditary and familial amyotrophic lateral sclerosis in Bulgaria. Dissertation, Medical University-Sofia"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03576-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:03:18Z","timestamp":1700596998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03576-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3576"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03576-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"12 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Committee at the Medical University of Sofia (RECMUS) with a certification no.1480\/14.05.2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}